Prognostic utility of brain natriuretic peptide in asymptomatic patients with significant mitral regurgitation and preserved left ventricular ejection fraction

Amgad Mentias, Krishna Patel, Harsh Patel, A. Marc Gillinov, L. Leonardo Rodriguez, Lars G. Svensson, Tomislav Mihaljevic, Joseph F. Sabik, Brian P. Griffin, Milind Y. Desai

Research output: Contribution to journalArticle

Abstract

We sought to study the prognostic utility of serum brain natriuretic peptide (BNP) in patients with significant primary mitral regurgitation (MR) and preserved left ventricular (LV) ejection fraction (EF). Consecutive 548 asymptomatic patients (age 62 ± 13 years and 66% men) with ≥3 + primary MR and preserved LVEF on echo at rest, evaluated at our center from 2005 to 2008 were studied. Baseline clinical and echo data were recorded and the Society of Thoracic Surgeons (STS) score was calculated. Mean STS score was 4 ± 1%. Mean LVEF, mitral effective regurgitant orifice, indexed LV end-systolic diameter, and right ventricular systolic pressure (RVSP) were 62 ± 4%, 0.55 ± 0.3 cm2, 1.6 ± 0.3 cm/m2, and 38 ± 15 mm Hg; 43% had flail. Median log-transformed brain natriuretic peptide (lnBNP) was 4.1 (interquartile range 3.30 to 5.0), corresponding to an absolute BNP value of 60 pg/ml (only 13% had an absolute BNP value >250 pg/ml). At 7.4 ± 2 years, 493 patients (90%) had mitral surgery (92% repair) and nonmalignancy death occurred in 53 patients (10%). On multivariate Cox analysis, higher STS score (hazard ratio [HR] 1.50, 95% CI 1.20 to 1.88), higher baseline RVSP (HR 1.17, 95% CI 1.02 to 1.35), and higher ln BNP (HR 2.51, 95% CI 1.86 to 3.39) predicted death, whereas mitral surgery (HR 0.17, 95% CI 0.09 to 0.30) was associated with improved survival (all p 4.1. Addition of lnBNP to a model of STS score, baseline RVSP, and mitral surgery provided incremental prognostic utility (chi-square for mortality increased from 137 to 162, p

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
JournalThe American Journal of Cardiology
Volume117
Issue number2
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Brain Natriuretic Peptide
Mitral Valve Insufficiency
Stroke Volume
Ventricular Pressure
Thorax
Blood Pressure
Multivariate Analysis
Survival
Mortality
Serum
Surgeons

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic utility of brain natriuretic peptide in asymptomatic patients with significant mitral regurgitation and preserved left ventricular ejection fraction. / Mentias, Amgad; Patel, Krishna; Patel, Harsh; Gillinov, A. Marc; Rodriguez, L. Leonardo; Svensson, Lars G.; Mihaljevic, Tomislav; Sabik, Joseph F.; Griffin, Brian P.; Desai, Milind Y.

In: The American Journal of Cardiology, Vol. 117, No. 2, 2016, p. 258-263.

Research output: Contribution to journalArticle

Mentias, A, Patel, K, Patel, H, Gillinov, AM, Rodriguez, LL, Svensson, LG, Mihaljevic, T, Sabik, JF, Griffin, BP & Desai, MY 2016, 'Prognostic utility of brain natriuretic peptide in asymptomatic patients with significant mitral regurgitation and preserved left ventricular ejection fraction', The American Journal of Cardiology, vol. 117, no. 2, pp. 258-263. https://doi.org/10.1016/j.amjcard.2015.10.040
Mentias, Amgad ; Patel, Krishna ; Patel, Harsh ; Gillinov, A. Marc ; Rodriguez, L. Leonardo ; Svensson, Lars G. ; Mihaljevic, Tomislav ; Sabik, Joseph F. ; Griffin, Brian P. ; Desai, Milind Y. / Prognostic utility of brain natriuretic peptide in asymptomatic patients with significant mitral regurgitation and preserved left ventricular ejection fraction. In: The American Journal of Cardiology. 2016 ; Vol. 117, No. 2. pp. 258-263.
@article{e543cadf59b4428191924c67d66412ab,
title = "Prognostic utility of brain natriuretic peptide in asymptomatic patients with significant mitral regurgitation and preserved left ventricular ejection fraction",
abstract = "We sought to study the prognostic utility of serum brain natriuretic peptide (BNP) in patients with significant primary mitral regurgitation (MR) and preserved left ventricular (LV) ejection fraction (EF). Consecutive 548 asymptomatic patients (age 62 ± 13 years and 66{\%} men) with ≥3 + primary MR and preserved LVEF on echo at rest, evaluated at our center from 2005 to 2008 were studied. Baseline clinical and echo data were recorded and the Society of Thoracic Surgeons (STS) score was calculated. Mean STS score was 4 ± 1{\%}. Mean LVEF, mitral effective regurgitant orifice, indexed LV end-systolic diameter, and right ventricular systolic pressure (RVSP) were 62 ± 4{\%}, 0.55 ± 0.3 cm2, 1.6 ± 0.3 cm/m2, and 38 ± 15 mm Hg; 43{\%} had flail. Median log-transformed brain natriuretic peptide (lnBNP) was 4.1 (interquartile range 3.30 to 5.0), corresponding to an absolute BNP value of 60 pg/ml (only 13{\%} had an absolute BNP value >250 pg/ml). At 7.4 ± 2 years, 493 patients (90{\%}) had mitral surgery (92{\%} repair) and nonmalignancy death occurred in 53 patients (10{\%}). On multivariate Cox analysis, higher STS score (hazard ratio [HR] 1.50, 95{\%} CI 1.20 to 1.88), higher baseline RVSP (HR 1.17, 95{\%} CI 1.02 to 1.35), and higher ln BNP (HR 2.51, 95{\%} CI 1.86 to 3.39) predicted death, whereas mitral surgery (HR 0.17, 95{\%} CI 0.09 to 0.30) was associated with improved survival (all p 4.1. Addition of lnBNP to a model of STS score, baseline RVSP, and mitral surgery provided incremental prognostic utility (chi-square for mortality increased from 137 to 162, p",
author = "Amgad Mentias and Krishna Patel and Harsh Patel and Gillinov, {A. Marc} and Rodriguez, {L. Leonardo} and Svensson, {Lars G.} and Tomislav Mihaljevic and Sabik, {Joseph F.} and Griffin, {Brian P.} and Desai, {Milind Y.}",
year = "2016",
doi = "10.1016/j.amjcard.2015.10.040",
language = "English (US)",
volume = "117",
pages = "258--263",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Prognostic utility of brain natriuretic peptide in asymptomatic patients with significant mitral regurgitation and preserved left ventricular ejection fraction

AU - Mentias, Amgad

AU - Patel, Krishna

AU - Patel, Harsh

AU - Gillinov, A. Marc

AU - Rodriguez, L. Leonardo

AU - Svensson, Lars G.

AU - Mihaljevic, Tomislav

AU - Sabik, Joseph F.

AU - Griffin, Brian P.

AU - Desai, Milind Y.

PY - 2016

Y1 - 2016

N2 - We sought to study the prognostic utility of serum brain natriuretic peptide (BNP) in patients with significant primary mitral regurgitation (MR) and preserved left ventricular (LV) ejection fraction (EF). Consecutive 548 asymptomatic patients (age 62 ± 13 years and 66% men) with ≥3 + primary MR and preserved LVEF on echo at rest, evaluated at our center from 2005 to 2008 were studied. Baseline clinical and echo data were recorded and the Society of Thoracic Surgeons (STS) score was calculated. Mean STS score was 4 ± 1%. Mean LVEF, mitral effective regurgitant orifice, indexed LV end-systolic diameter, and right ventricular systolic pressure (RVSP) were 62 ± 4%, 0.55 ± 0.3 cm2, 1.6 ± 0.3 cm/m2, and 38 ± 15 mm Hg; 43% had flail. Median log-transformed brain natriuretic peptide (lnBNP) was 4.1 (interquartile range 3.30 to 5.0), corresponding to an absolute BNP value of 60 pg/ml (only 13% had an absolute BNP value >250 pg/ml). At 7.4 ± 2 years, 493 patients (90%) had mitral surgery (92% repair) and nonmalignancy death occurred in 53 patients (10%). On multivariate Cox analysis, higher STS score (hazard ratio [HR] 1.50, 95% CI 1.20 to 1.88), higher baseline RVSP (HR 1.17, 95% CI 1.02 to 1.35), and higher ln BNP (HR 2.51, 95% CI 1.86 to 3.39) predicted death, whereas mitral surgery (HR 0.17, 95% CI 0.09 to 0.30) was associated with improved survival (all p 4.1. Addition of lnBNP to a model of STS score, baseline RVSP, and mitral surgery provided incremental prognostic utility (chi-square for mortality increased from 137 to 162, p

AB - We sought to study the prognostic utility of serum brain natriuretic peptide (BNP) in patients with significant primary mitral regurgitation (MR) and preserved left ventricular (LV) ejection fraction (EF). Consecutive 548 asymptomatic patients (age 62 ± 13 years and 66% men) with ≥3 + primary MR and preserved LVEF on echo at rest, evaluated at our center from 2005 to 2008 were studied. Baseline clinical and echo data were recorded and the Society of Thoracic Surgeons (STS) score was calculated. Mean STS score was 4 ± 1%. Mean LVEF, mitral effective regurgitant orifice, indexed LV end-systolic diameter, and right ventricular systolic pressure (RVSP) were 62 ± 4%, 0.55 ± 0.3 cm2, 1.6 ± 0.3 cm/m2, and 38 ± 15 mm Hg; 43% had flail. Median log-transformed brain natriuretic peptide (lnBNP) was 4.1 (interquartile range 3.30 to 5.0), corresponding to an absolute BNP value of 60 pg/ml (only 13% had an absolute BNP value >250 pg/ml). At 7.4 ± 2 years, 493 patients (90%) had mitral surgery (92% repair) and nonmalignancy death occurred in 53 patients (10%). On multivariate Cox analysis, higher STS score (hazard ratio [HR] 1.50, 95% CI 1.20 to 1.88), higher baseline RVSP (HR 1.17, 95% CI 1.02 to 1.35), and higher ln BNP (HR 2.51, 95% CI 1.86 to 3.39) predicted death, whereas mitral surgery (HR 0.17, 95% CI 0.09 to 0.30) was associated with improved survival (all p 4.1. Addition of lnBNP to a model of STS score, baseline RVSP, and mitral surgery provided incremental prognostic utility (chi-square for mortality increased from 137 to 162, p

UR - http://www.scopus.com/inward/record.url?scp=84961872539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961872539&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.10.040

DO - 10.1016/j.amjcard.2015.10.040

M3 - Article

C2 - 26651455

AN - SCOPUS:84961872539

VL - 117

SP - 258

EP - 263

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 2

ER -